This website uses cookies to offer you the best possible user experience. Cookies’ information is stored in your browser and performs functions such as recognizing when you return to our website or helping our team to understand which sections of the website you find most interesting and useful. More information in the privacy policy and cookie policy!
Labiana adds a new injectable antibiotic with no waiting times for cattle to its portfolio.
- This antibiotic, classified as category C, has great therapeutic versatility for cattle, dogs, and cats.
- With this, Labiana strengthens its animal health portfolio with an innovative product, in line with the objectives of its strategic plan.
Madrid, March 25, 2025 – Labiana, the pharmaceutical laboratory specialized in animal and human health listed on BME Growth, has added Lexylan, a new antibiotic classified as Category C in its prescription guidelines, to its product portfolio. This antibiotic is for the treatment of infections in cattle and small animals (dogs and cats), as announced during Figan, the International Fair for Animal Production, currently being held in Zaragoza.
It is the only injectable cephalosporin registered for cattle in the Category C antibiotics group. It is also the only injectable antibiotic in the Category C and D prescription categories (caution and prudence) specifically developed to require no waiting time in dairy cattle.
All of these features not only improve the welfare and quality of life of the animals but also assist farmers, as the 0-day withdrawal time in milk (dairyt cow) optimizes productivity on farms, allowing milk to be marketed from the day the treatment begins.
Moreover, this antibiotic has significant therapeutic versatility. It is prescribed to treat dermatological infections, metritis, wounds, abscesses, and septic mastitis in cattle, as well as to treat respiratory tract infections, urogenital system infections, skin infections, soft tissue infections, and gastrointestinal system infections in dogs and cats.
Labiana strengthens its animal health division with this solution, which is in line with its strategic plan and one of its main objectives: to consolidate and develop a differentiated portfolio based on two key pillars: the quality and innovation of its products.
According to Jose Peñalver, veterinarian and Export Business Development at Labiana, “This new antibiotic strengthens Labiana’s pipeline in the animal health area with a product that has no waiting time, making the work of veterinarians and farmers easier by not altering their workflows or impacting the productivity of farms, thus avoiding direct losses. At the same time, it contributes to improving the quality of life of the animals it is prescribed for.”
About Labiana
About Labiana
Labiana Health is a leading international, independent, and integrated platform in the animal and human health industries, with a diversified product and business portfolio and a wide range of high-level clients with whom it shares long-term trust-based relationships.
Currently, the Group’s products are in more than 150 markets, with registrations in over 114 countries thanks to its two GMP (“Good Manufacturing Practice”) manufacturing plants located in Spain, its international subsidiaries in Turkey, Ecuador, and Mexico, its participation in Serbia, its growing network of multinational clients, and its licensing agreements with international distributors for the sale of its products.
The group has two differentiated and complementary business lines: contract manufacturing, which provides stability and visibility of revenues, and the development, manufacturing, and commercialization of products, which drive growth. The company debuted on BME Growth in June 2022, becoming the first veterinary company to list on the BME Growth Market in Spain.
Leave a Comment